AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21095491
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (recombinant human erythropoietin 4000 IU SC)
Trial: 21095491
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (recombinant human erythropoietin 4000 IU SC)
Trial: 15705086
Drug: Tolterodine (antimuscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (antimuscarinic drug)
Trial: 12939945
Drug: Perftoran and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perftoran and cytoflavin (added to therapy scheme)
Trial: 12939945
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (intensive therapy without metabolic antihypoxants)
Trial: 6536840
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of potassium chloride
Trial: 6536840
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of potassium/magnesium chloride
Trial: 6536840
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of potassium-(D,L)-aspartate
Trial: 6536840
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of potassium/magnesium-(D,L)-aspartate
Trial: 31374218
Drug: Suvorexant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (10 mg week 1, 20 mg week 2)
Trial: 29916560
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure medications (specific drugs not mentioned)
Trial: 29916560
Drug: Testing medications
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing medications thoroughly in both sexes
Trial: 1410147
Drug: Tryptophan-deficient amino
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan-deficient amino acid mixture (4.5 hours before morphine administration)
Trial: 1410147
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg intramuscularly)
Trial: 3904654
Drug: Triamterene, 50
RxNorm normalized name: Triamterene, 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene, 50 to 200 mg daily
Trial: 3904654
Drug: Triamterene added
RxNorm normalized name: Triamterene
DrugBank: Triamterene (DB00384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamterene added to diuretic therapy
Trial: 21232723
Drug: Combination-facilitated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-facilitated group (abciximab with half-dose reteplase)
Trial: 21232723
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI group (no pre-treatment)
Trial: 18081147
Drug: Alexandrite laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alexandrite laser treatment
Trial: 15605283
Drug: Oral desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral desmopressin 400 mug (group 2)
Trial: 15605283
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (group 3)
Trial: 11828811
Drug: Long-acting beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta 2-agonists
Trial: 9238877
Drug: Mouthrinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthrinsing with 20 ml distilled water
Trial: 29621979
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with volar locking plate
Trial: 29621979
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment with cast immobilization
Trial: 21656179
Drug: Split-dose polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose polyethylene glycol (PEG) (2 L/2 L)
Trial: 21656179
Drug: Split-dose aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose aqueous sodium phosphate (NaP) (45 mL/45 mL, 12 h apart)
Trial: 14610480
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy (grass pollen immunotherapy)
Trial: 10731916
Drug: SS-cream 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS-cream 0.05 gm
Trial: 10731916
Drug: SS-cream 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS-cream 0.10 gm
Trial: 10731916
Drug: SS-cream 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS-cream 0.15 gm
Trial: 10731916
Drug: SS-cream 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS-cream 0.20 gm
Trial: 9188946
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (specific immunotherapy)
Trial: 12959296
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tablet
Trial: 12959296
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tablet
Trial: 12959296
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg (2 x 250 mg)
Trial: 12959296
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg immediately following a standard meal
Trial: 29242014
Drug: Omalizumab combined
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab combined with multifood oral immunotherapy (n=36)
Trial: 29209154
Drug: Caffeinated supplement
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated supplement
Trial: 29209154
Drug: Non-caffeinated supplement
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-caffeinated supplement
Trial: 20854954
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus GP IIb/IIIa inhibitor
Trial: 20854954
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus GP IIb/IIIa inhibitor
Trial: 18238736
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 50,000 IU once weekly for 12 weeks
Trial: 10776745
Drug: Artemether 6
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether 6 mg/kg orally six times once every 3 weeks
Trial: 10776745
Drug: Artemether 6
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether 6 mg/kg
Trial: 11885225
Drug: Self brushing
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self brushing with acidulated phosphate fluoride (APF) gel (pH 5.6; concentration: 4520 ppm of ion F‐)
Trial: 23763894
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder
Trial: 17692744
Drug: BG9928 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (3, 15, 75, or 225 mg)
Trial: 17692744
Drug: BG9928 (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (15, 75, or 225 mg)
Trial: 17692744
Drug: BG9928 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9928 (3 to 225 mg)
Trial: 15174010
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPD) 0.4 mg/kg orally
Trial: 15174010
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPD) 0.4 mg/kg orally coadministered with levodopa (0.5 mg/kg/hr)
Trial: 2412045
Drug: Ketanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (10 mg i.v.)
Trial: 2102133
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg/b.i.d.)
Trial: 28768250
Drug: L. gasseri
RxNorm normalized name: Lactobacillus crispatus/L. gasseri/L. jensenii/L. rhamnosus 5 billion cell ORAL CAPSULE
DrugBank: Lactobacillus gasseri (DB16543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. gasseri OLL2716 group
Trial: 1661645
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (0.07 units/kg at night)
Trial: 7041324
Drug: Carbimazole 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole 80 mg daily for two months
Trial: 29623143
Drug: Nalbuphine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (15 μg·kg‐1·ml‐1) with flurbiprofen
Trial: 25149899
Drug: Needle aponeurotomy
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle aponeurotomy combined with triamcinolone injections
Trial: 20074380
Drug: Agarose gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agarose gel electrophoresis
Trial: 16026123
Drug: Concomitant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant drugs
Trial: 11802045
Drug: Ketoprofen (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (0.5 mg/kg bolus intravenously, followed by 3 mg/kg continuous infusion over 24 hours, and 3 to 5 mg/kg per day at home)
Trial: 11802045
Drug: Ketoprofen combined
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen combined with paracetamol-codeine
Trial: 11802045
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and oxycodone (control group)
Trial: 2269542
Drug: DPI 201‐106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI 201‐106 (20 mg)
Trial: 2269542
Drug: DPI 201‐106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI 201‐106 (40 mg)
Trial: 6308702
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg i.v.)
Trial: 6308702
Drug: Apomorphine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (20 micrograms/kg/hr) for 40 min by i.v. infusion
Trial: 28799413
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Treatment for Depression (BATD-HIV)
Trial: 26857924
Drug: Standard concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL regimen)
Trial: 26857924
Drug: Experimental sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental sequential bevacizumab given 4 days before chemotherapy
Trial: 23218935
Drug: Bupivacaine .5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine .5% with ketorolac .6 mg/hour
Trial: 23218935
Drug: Bupivacaine .5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine .5% with hydromorphone .04 mg/hour
Trial: 20824678
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg saxagliptin once daily for 18 weeks
Trial: 20824678
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin once daily for 18 weeks
Trial: 20824678
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg saxagliptin plus metformin
Trial: 20824678
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin plus metformin
Trial: 18410225
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate 1000 mg/day + vitamin D(2) 1000 IU
Trial: 18410225
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate 1000 mg/day + placebo
Trial: 12724503
Drug: Sertraline (N=70)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (N=70)
Trial: 1930344
Drug: Kava extract
RxNorm normalized name: Kava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava extract WS 1490 (Laitan) 3 x 100 mg/day
Trial: 7149056
Drug: Intravenous haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous haloperidol
Trial: 31776310
Drug: Mail-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mail-based intervention using the TAKE10! Program (monthly mail with self-check sheets and feedback for 5 months)
Trial: 22081481
Drug: saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 5 mg daily
Trial: 17403312
Drug: Propofol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (60 ml/min)
Trial: 15188109
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of tranexamic acid
Trial: 2642497
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (900 micrograms/m2 subcutaneously twice weekly for eight doses)
Trial: 31568997
Drug: Integrated home-visitation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated home-visitation program delivered by community health workers including psychosocial stimulation and health promotion during bi-weekly home visits over one year.
Trial: 21302042
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of enteric-coated pantoprazole
Trial: 16186075
Drug: Intranasal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17beta‐estradiol (Aerodiol) administration
Trial: 12519853
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate 3.6 mg by sc injection every 4 weeks for 12 weeks (Group 1)
Trial: 12519853
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus transdermal testosterone (Androderm 5 mg topically daily) (Group 2)
Trial: 12519853
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus testosterone plus an aromatase inhibitor (anastrozole 1 mg orally daily) (Group 3)
Trial: 10992176
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (2 mg 17beta-estradiol plus 1 mg norethindrone acetate daily)
Trial: 1475038
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 0.25 mg rolipram/day
Trial: 1475038
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 0.50 mg rolipram/day
Trial: 1475038
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 1.00 mg rolipram/day
Trial: 28856388
Drug: Polidocanol injections
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polidocanol injections
Trial: 26598571
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment schedules (specific dosage and duration not mentioned)
Trial: 22993930
Drug: Clarithromycin plus
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin plus standard antibacterial therapy (3rd generation cephalosporins)
Trial: 22993930
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial therapy (3rd generation cephalosporins)
Trial: 19915829
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg (nighttime dosing)
Trial: 19915829
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg (daytime dosing)
Trial: 19915829
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of nighttime vs daytime dosing
Trial: 12775860
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 250 micro g administered twice daily
Trial: 10684846
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group: children with strabismus)
Trial: 9085945
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg bolus followed by an infusion of 5 mg/h for 24 h
Trial: 11981600
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg methadone
Trial: 3536377
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg methadone
Trial: 3536377
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg methadone
Trial: 29231565
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of human placenta tissue fluid combined with oral administration of metformin hydrochloride enteric-coated tablets
Trial: 29231565
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of metformin hydrochloride enteric-coated tablets
Trial: 22615527
Drug: Oxitropium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium 0.2 mg x 3 mg
Trial: 10999066
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg i.v. prior to chemotherapy followed by two further doses of 8 mg i.v. over the first 24 hours, then 8 mg b.d. orally for the next 5 days
Trial: 10999066
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg i.v. prior to chemotherapy followed by 2 i.v. doses of 10 mg each, 4 hours apart, then 20 mg orally for the next 5 days
Trial: 1649672
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (NOVO)
Trial: 3073903
Drug: Monocomponent porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monocomponent porcine insulin
Trial: 30292891
Drug: Adjunctive urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive urine LAM testing (n=1257)
Trial: 30292891
Drug: Routine diagnostics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine diagnostics plus adjunctive urine LAM testing (n=1257)
Trial: 19224163
Drug: Anluohuaxian tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anluohuaxian tablet + gamma-IFN
Trial: 19224163
Drug: Anluohuaxian tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anluohuaxian tablet
Trial: 19224163
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (anluohuaxian tablet + gamma-IFN)
Trial: 17966930
Drug: Conventional cytopathology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cytopathology of oral brush biopsies
Trial: 11726432
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B complex (folate 2.5 mg, B(6) 25 mg, and B(12) 500 microg) daily for 1 week before surgery
Trial: 8485020
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MTX i.v.
Trial: 8485020
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MTX i.m.
Trial: 8485020
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MTX p.o.
Trial: 8485020
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MTX (all routes)
Trial: 3318348
Drug: Ketotifen 2
RxNorm normalized name: ketotifen 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 2 mg/day for 7 days
Trial: 31273290
Drug: Low-dose AA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AA (250 mg)
Trial: 30264056
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of amino acid and sodium hyaluronate gel